Adding a drug called evolocumab to cholesterol-lowering statins can lower the chances of serious heart problems by 20% in people who already have heart disease.
Strongly supported
Multiple high-quality studies back this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
Adding a drug called evolocumab to cholesterol-lowering statins can lower the chances of serious heart problems by 20% in people who already have heart disease.
See the technical phrasing
In patients with established cardiovascular disease, the addition of evolocumab to statin therapy reduces the risk of major adverse cardiovascular events by 20% compared to statin therapy alone.
What the research says
Supports
3 studies
Study: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
This study provides evidence supporting the claim.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 3 supporting studies